In a recent press release, Fortress Biotech, Inc.announced that its Board of Directors has decided to pause the payment of dividends on the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock until further notice.This decision has raised concerns among shareholders, as dividends on the Series A Preferred Stock will continue to accrue and cumulate until further authorization or declaration.
This news comes on the heels of previous announcements that have had a negative impact on Fortress Biotech Inc stock.Following the announcement, the stock dropped by -1.18%, adding to a year-over-year decline of -80.37%. Currently trading on the NASDAQ, the stock is -52.9% below its 52-week average.
The decision to pause dividend payments on the Series A Preferred Stock is likely to have a significant impact on shareholders who rely on these payments for income.It raises questions about the financial stability and long-term strategy of Fortress Biotech, Inc.and may lead to further uncertainty among investors.
As the company navigates these challenges, shareholders will be closely watching for updates and future actions from Fortress Biotech, Inc.’s Board of Directors.The decision to pause dividend payments underscores the importance of monitoring and evaluating investment decisions in the ever-evolving landscape of the biopharmaceutical industry.
Comments